{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:29:16Z","timestamp":1793647756692,"version":"4.5.1"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shandong Provincial Traditional Chinese Medicine Science and Technology Project","award":["M-2023119"],"award-info":[{"award-number":["M-2023119"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,16]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Aplastic anemia-paroxysmal nocturnal hemoglobinuria (AA-PNH) syndrome is a rare acquired hematopoietic stem cell disorder. Patients who respond poorly to conventional immunosuppressive therapy (IST) and corticosteroids face limited therapeutic options and a poor prognosis. This article reports on the use of iptacopan combined with IST for AA-PNH syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A previously healthy 24-year-old Han Chinese male presented with dizziness and fatigue and was found to have pancytopenia. He was initially treated with cyclosporine. However, 2 years after discontinuation, he developed acute hemolysis. After treatment with iptacopan, the patient\u2019s hemolysis was quickly controlled, but he still required blood transfusions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>The patient was initially diagnosed with aplastic anemia through bone marrow examination, along with a paroxysmal nocturnal hemoglobinuria clone. After recurrent acute hemolysis, reexamination of the bone marrow and flow cytometry revealed partial deficiency of cluster of differentiation (CD) 55\/CD59, and fluorescently labeled aerolysin-negative cells accounted for more than 90% of granulocytes and monocytes. Eventually, the diagnosis of AA-PNH syndrome was made.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>After acute hemolysis was initially managed with steroids and IST, the patient was started on iptacopan to achieve rapid hemolysis control. Given persistent transfusion dependence due to bone marrow hypoplasia, immunosuppressants and hematopoietic stimulants (danazol and eltrombopag) were added while continuing iptacopan. The hematopoietic stimulants were discontinued after 3 months due to abnormal liver function tests, and the patient was maintained on iptacopan combined with IST.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Iptacopan rapidly and effectively controlled hemolysis, and no breakthrough hemolysis, extravascular hemolysis, or drug-related adverse events were observed. Critically, iptacopan served as a bridge to control hemolysis, while the subsequent addition of IST (tacrolimus\/cyclosporine) addressed the underlying autoimmune bone marrow failure. After combined treatment with iptacopan and IST, the patient\u2019s blood cell count gradually recovered, hemoglobin returned to normal levels, and blood transfusion was no longer required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case suggests that iptacopan combined with IST may represent a potentially effective and safe therapeutic option for AA-PNH syndrome that is refractory to conventional IST and corticosteroids. Especially for AA-PNH patients with impaired bone marrow function and continuous dependence on blood transfusion, iptacopan combined with IST may be an effective and well-tolerated treatment regimen.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000051162","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:00:55Z","timestamp":1792173655000},"page":"e51162","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Iptacopan combined with immunosuppressive therapy for aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7593-4163","authenticated-orcid":false,"given":"Xiaoqian","family":"Liu","sequence":"first","affiliation":[{"name":"The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linying","family":"Li","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5637-2190","authenticated-orcid":false,"given":"Zhaoxia","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261102","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood-2016-09-740845","article-title":"Glycosylphosphatidylinositol-specific T cells, IFN-\u03b3-producing T cells, and pathogenesis of idiopathic aplastic anemia.","volume":"129","author":"Gargiulo","year":"2017","journal-title":"Blood"},{"key":"R2-20261102","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/ejh.12299","article-title":"Detection of paroxysmal nocturnal hemoglobinuria clones to exclude inherited bone marrow failure syndromes.","volume":"92","author":"DeZern","year":"2014","journal-title":"Eur J Haematol"},{"key":"R3-20261102","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3324\/haematol.2009.017889","article-title":"Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine.","volume":"95","author":"Scheinberg","year":"2010","journal-title":"Haematologica"},{"key":"R4-20261102","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.seminhematol.2018.05.014","article-title":"C3-mediated extravascular hemolysis in PNH on eculizumab: mechanism and clinical implications.","volume":"55","author":"Notaro","year":"2018","journal-title":"Semin Hematol"},{"key":"R5-20261102","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1080\/14656566.2024.2404110","article-title":"Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria.","volume":"25","author":"de Castro","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"R6-20261102","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"key":"R7-20261102","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.3324\/haematol.2017.183046","article-title":"Concurrent treatment of aplastic anemia\/paroxysmal nocturnal hemoglobinuria syndrome with immunosuppressive therapy and eculizumab: a UK experience.","volume":"103","author":"Griffin","year":"2018","journal-title":"Haematologica"},{"key":"R8-20261102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000526979","article-title":"Concomitant immunosuppressive therapy and eculizumab use in patients with paroxysmal nocturnal hemoglobinuria: an international PNH registry analysis.","volume":"146","author":"Hill","year":"2023","journal-title":"Acta Haematol"},{"key":"R9-20261102","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/bmt.2017.220","article-title":"Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis.","volume":"53","author":"Pagliuca","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"R10-20261102","doi-asserted-by":"crossref","first-page":"12160","DOI":"10.3390\/ijms252212160","article-title":"Monitoring and treatment of paroxysmal nocturnal hemoglobinuria in patients with aplastic anemia in Asia: an expert consensus.","volume":"25","author":"Wong","year":"2024","journal-title":"Int J Mol Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000051162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:01:24Z","timestamp":1793646084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000051162"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":10,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000051162","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"2026-01-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}